 |
Recombinant protein inhibitor of complement factor 5 |
|---|---|
| Trade Name | |
| Orphan Indication | Guillain-Barré syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2016-05-10 00:00:00 |
| Sponsor | Akari Therapeutics Plc;24 West 40th Street, 8th Floor;New York, New York, 10018 |
